SHAREHOLDERS ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors Inotiv, Inc. - NOTV - Stock News Source

VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESS CABLE / July 18, 2022 / XPyto Therapeutics Corp. (CSE:XPHY),(OTCQB:XPHYF), (FSE:4XT) (“XPhyto” or the “Company”) is pleased to report a significant potential market opportunity for its Oral Soluble (“ODF”) Biosensor Screening Assays. ) for inflammation. Certain buprenorphine medications prescribed to treat opioid use disorder (“OUD”) and pain have recently been associated with numerous serious oral health problems requiring medical intervention. Buprenorphine is a drug approved by the US Food and Drug Administration (the “FDA”) to treat OUD as a Medication-Assisted Treatment (MAT). The number of American adolescents and adults with OUD in 2019 was estimated to be between 6.7 and 7.6 million. XPhyto is investigating the potential application of one or more of its ODF biosensor screening tests for oral inflammation to detect buprenorphine-related infections. dental problems.

Earlier this year, the FDA issued a Drug Safety Communication (“DSC”) entitled “FDA Warns of dental problems with buprenorphine medications dissolved in the mouth to treat pain and opioid use disorder.” The DSC notes that dental problems include “cavities, cavities, oral infections, and loss of teeth, can be serious and has been reported even in patients with no history of dental problems.” Despite the severity of side effects, the FDA recommends continued use of these medications because the benefits outweigh the risks and oral care can help. The global market for buprenorphine is expected to exceed USD 10.9 billion by 2027, according to Coherent Market Insights (CMI).

Sponsored Content:

XPyto’s proprietary ODF biosensor development portfolio includes multiple products for oral health, including detection of stomatitis, periodontitis and peri-implantitis. The company’s first ODF biosensor detection product is for general oral inflammation. Positive detection of the causative inflammatory agents results in an enzymatic release of a bitter compound into the user’s mouth, without the need for medical training, analytical equipment, or power supply. The Oral Inflammation Biosensor is designed to function as a simple, low-cost, self-administered screening test to identify users for follow-up medical testing. The company’s oral soluble inflammation screening test was registered in the EU in late 2021 and is currently licensed for marketing and sale in Europe.

The Company is currently investigating the potential application of one or more of its oral health biosensor screening tests for the detection of buprenorphine-related dental problems. The requirements for clinical evaluation for the purpose of registration and/or commercial approval will be announced once established. The company expects to provide more updates on its oral health and infectious disease testing programs in the coming weeks.

XPyto’s portfolio of biosensor detection products for inflammatory, bacterial, and viral infectious diseases includes stomatitis, peri-implantitis, periodontitis, group A streptococcus, influenza A, and covid-19. This suite of biosensor products positions the company within the global biosensor and oral health markets, which are expected to reach US$42 billion by 2027, according to Global Market Insights and MedicalExpo e-magazine and is projected to reach USD 698.8 billion by 2030.

About XPhyto Therapeutics Corp.
XPhyto Therapeutics Corp. is a diversified bioscience accelerator focused on next-generation drug formulation, diagnostics and new investment opportunities in active pharmaceutical ingredients, including: precision transdermal and oral soluble drug formulations; rapid, low-cost oral health and infectious disease screening tests; and manufacturing, standardization and evaluation of psychedelic compounds for the treatment of neurological conditions. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

Sponsored Content: is a veteran-owned e-commerce with over 40,000 items at great prices and always free shipping

XPyto Therapeutics Corp.
Hugh Rogers, CEO and Director
Email: [email protected]
Phone: +1 780-818-642

Dr. Raimar Löbenberg
Director, Center for Innovation and Development of Medicines
Faculty of Pharmacy and Pharmaceutical Sciences
Katz Group-Rexall Center for Research in Pharmacy and Health
university of alberta
11315 – 87th Avenue, Room 3-142-K
Edmonton, AB T6G 2T9
Telephone: 780 492 1255
Fax: 780 492 1217
Skype: raimarloebenberg

Forward-looking statements
This press release includes statements that contain forward-looking information within the meaning of applicable Canadian securities law (“forward-looking statements”). Forward-looking statements are often characterized by words such as “develop”, “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “potential”, “propose” and other similar words, or statements that certain events or conditions “may” or “will” occur, and in this release include the statement regarding the Company’s goal of building a successful diagnostics, drug delivery and cannabis company medicinal. Forward-looking statements are only predictions based on the opinions and estimates of management as of the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements, including: that the Company may not be successful in developing a commercial product; that the sale of products may not be a viable business; that the Company cannot scale its business; product liability risks; product regulatory risk; general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; currency risks; competition; international risks; and other risks beyond the control of the Company. The Company has no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Neither the CSE nor its Market Regulator (as that term is defined in the CSE’s policies) accepts responsibility for the adequacy or accuracy of this news release.

FONT: XPyto Therapeutics Corp.

See source version at access

Source link

Leave a Reply

Your email address will not be published.